Furthermore, recent clinical data from the NOA-9 phase III trial also support the rationale for combination alkylator strategies, demonstrating a survival benefit with the addition of lomustine to TMZ in newly diagnosed MGMT-silenced GBM, suggesting that combinations leading to both alkylation damage and DNA crosslinking may enhance antitumor efficacy95. The gene discussed is MGMT; the disease is glioblastoma.